Abcam plc (NASDAQ:ABCM – Get Rating) saw strong trading volume on Monday . 4,040 shares were traded during mid-day trading, a decline of 98% from the previous session's volume of 162,655 shares.The stock last traded at $15.12 and had previously closed at $14.62.
Wall Street Analysts Forecast Growth
Separately, Panmure Gordon upgraded Abcam from a "hold" rating to a "buy" rating in a report on Monday, September 5th.
Get
Abcam alerts:
Abcam Stock Up 0.1 %
The stock has a 50 day simple moving average of $14.82 and a two-hundred day simple moving average of $15.54.
Institutional Trading of Abcam
A number of hedge funds and other institutional investors have recently bought and sold shares of ABCM. HM Payson & Co. acquired a new stake in Abcam in the fourth quarter valued at $29,000. 1832 Asset Management L.P. acquired a new stake in Abcam in the first quarter valued at $32,000. National Bank of Canada FI increased its position in shares of Abcam by 71.3% during the second quarter. National Bank of Canada FI now owns 2,777 shares of the company's stock worth $40,000 after purchasing an additional 1,156 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Abcam by 48.7% during the first quarter. JPMorgan Chase & Co. now owns 3,044 shares of the company's stock worth $56,000 after purchasing an additional 997 shares in the last quarter. Finally, Advisor Group Holdings Inc. increased its position in shares of Abcam by 20.5% during the fourth quarter. Advisor Group Holdings Inc. now owns 5,876 shares of the company's stock worth $138,000 after purchasing an additional 999 shares in the last quarter. 11.82% of the stock is currently owned by institutional investors and hedge funds.
Abcam Company Profile
(Get Rating)
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.
Read More
- Get a free copy of the StockNews.com research report on Abcam (ABCM)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.
